Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bruker Yönetim

Yönetim kriter kontrolleri 4/4

Bruker's CEO'su Frank Laukien, Feb1991 tarihinde atandı, in görev süresi 33.67 yıldır. in toplam yıllık tazminatı $ 5.86M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.8% maaş ve 84.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 26.59% ine doğrudan sahiptir ve bu hisseler $ 2.78B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.5 yıl ve 9.2 yıldır.

Anahtar bilgiler

Frank Laukien

İcra Kurulu Başkanı

US$5.9m

Toplam tazminat

CEO maaş yüzdesi	15.8%
CEO görev süresi	33.7yrs
CEO sahipliği	26.6%
Yönetim ortalama görev süresi	10.5yrs
Yönetim Kurulu ortalama görev süresi	9.2yrs

Son yönetim güncellemeleri

Recent updates

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Jun 09

Bruker: A Confusing Acquisition Spree

May 31

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

May 09

Bruker Corporation: An Aggressive Acquisition Strategy

Apr 24

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Apr 11

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Jan 22

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Jan 08

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Dec 26

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Nov 06

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Oct 23

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Sep 25

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26

CEO Tazminat Analizi

Frank Laukien'un ücretlendirmesi Bruker'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$352m
Mar 31 2024	n/a	n/a	US$402m
Dec 31 2023	US$6m	US$926k	US$427m
Sep 30 2023	n/a	n/a	US$319m
Jun 30 2023	n/a	n/a	US$319m
Mar 31 2023	n/a	n/a	US$312m
Dec 31 2022	US$5m	US$873k	US$297m
Sep 30 2022	n/a	n/a	US$275m
Jun 30 2022	n/a	n/a	US$274m
Mar 31 2022	n/a	n/a	US$282m
Dec 31 2021	US$6m	US$812k	US$277m
Sep 30 2021	n/a	n/a	US$270m
Jun 30 2021	n/a	n/a	US$238m
Mar 31 2021	n/a	n/a	US$204m
Dec 31 2020	US$4m	US$689k	US$158m
Sep 30 2020	n/a	n/a	US$158m
Jun 30 2020	n/a	n/a	US$165m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$753k	US$197m
Sep 30 2019	n/a	n/a	US$207m
Jun 30 2019	n/a	n/a	US$189m
Mar 31 2019	n/a	n/a	US$184m
Dec 31 2018	US$4m	US$731k	US$180m
Sep 30 2018	n/a	n/a	US$98m
Jun 30 2018	n/a	n/a	US$92m
Mar 31 2018	n/a	n/a	US$84m
Dec 31 2017	US$5m	US$704k	US$79m

Tazminat ve Piyasa: Frank 'nin toplam tazminatı ($USD 5.86M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 13.04M ).

Tazminat ve Kazançlar: Frank 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Frank Laukien (64 yo)

33.7yrs

Görev süresi

US$5,858,761

Tazminat

Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Laukien	Chairman	33.7yrs	US$5.86m	26.59% $ 2.7b
Gerald Herman	Executive VP & CFO	6.6yrs	US$2.20m	0.033% $ 3.3m
Mark Munch	Corporate Executive VP and President of Bruker Nano Group & Corporate	9.3yrs	US$2.73m	0.050% $ 5.1m
Juergen Srega	President of Bruker CALID Group & Bruker Daltonics Division	11.8yrs	US$1.47m	0.081% $ 8.3m
Falko Busse	President of Bruker BioSpin Group	6.4yrs	US$1.35m	0.016% $ 1.6m
Justin Ward	Senior Director of Investor Relations & Corporate Development	no data	Veri yok	Veri yok
J. Alldredge	General Counsel & Secretary	no data	Veri yok	Veri yok
Burkhard Prause	President and CEO of Bruker Energy & Supercon Technologies	16.5yrs	US$967.91k	0.0090% $ 918.2k

10.5yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: BRKR 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Laukien	Chairman	33.7yrs	US$5.86m	26.59% $ 2.7b
John Ornell	Independent Director	9.2yrs	US$241.01k	0.014% $ 1.4m
Robert Rosenthal	Independent Director	8.9yrs	US$224.01k	0.019% $ 1.9m
Richard Packer	Independent Director	17.4yrs	US$227.32k	0.047% $ 4.8m
William Linton	Independent Lead Director	24.7yrs	US$231.01k	0.022% $ 2.2m
Adelene Perkins	Independent Director	7.4yrs	US$224.01k	0.013% $ 1.3m
Hermann Requardt	Independent Director	9.2yrs	US$219.01k	0.014% $ 1.4m
Bonnie Anderson	Independent Director	4.1yrs	US$219.65k	0.0050% $ 515.8k
Cynthia Friend	Independent Director	8.4yrs	US$216.83k	0.0076% $ 781.3k

9.2yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BRKR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.2 yıldır).

Bruker Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bruker Corporation, Annual General Meeting, May 30, 2024

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Insider notifies of intention to sell stock

Chairman exercised options to buy US$3.4m worth of stock.

Insufficient new directors

Recent updates

Bruker Corporation (NasdaqGS:BRKR) acquired Dynamic Biosensors GmbH.

We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt

Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In

Second quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Cash Dividend, Payable on September 16, 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Bruker Corporation to Report Q2, 2024 Results on Aug 06, 2024

Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker Corporation Announces Suspension of Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany

Bruker Corporation Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut Für Molekulare Pharmakologie (FMP) in Berlin

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Bruker Corporation Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker: A Confusing Acquisition Spree

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

Bruker Corporation has completed a Follow-on Equity Offering.

First quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Dividend, Payable on June 17, 2024

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bruker Corporation Revises Earnings Guidance for the Year 2024

Now 23% undervalued after recent price drop

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation: An Aggressive Acquisition Strategy

Bruker Corporation, Annual General Meeting, May 30, 2024

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Insider notifies of intention to sell stock

Fourth quarter dividend of US$0.05 announced

Consensus EPS estimates increase by 25%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman exercised options to buy US$3.4m worth of stock.

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Price target decreased by 8.7% to US$80.89

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Chairman notifies of intention to sell stock

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023